

Michal Neeman

michal.neeman@weizmann.ac.il

Cancer: An angiogenic disease?

ESMO-EA CR Joint symposium:

Targeted therapies: Promises,
successes and failures




Disclosure slide

- No Conflicts of Interest to declare

Cancer: An angiogenic disease?



- Angiogenic switch- tumor exit from dormancy
- Angiogenesis and tumor progression
- Angiogenesis and metastasis
- Angiogenesis and response to therapy
- Tumor vascularization, beyond angiogenesis
- Angiogenesis and tumor detection



The angiogenic switch hypothesis

Judah Folkman 1933-2008


Tumor angiogenesis



Folkman J, Merler E, Abernathy C, Williams G. Isolation of a tumor factor responsible for angiogenesis. J Exp Med. 1971;133:275-288.





Inducing angiogenesis



MRI of Hif-1 in tumor angiogenesis


$\text{hif-1} \square \alpha^{+/+}$

$\text{hif-1} \square \alpha^{-/-}$



BOLD contrast MRI

Functional vessels detected by signal change in response to hyperoxia.



Carmeliet et al Nature 1998

VIENNA
2012

ESMO congress

www.esmo2012.org

מכון ויצמן למדע
WEIZMANN INSTITUTE OF SCIENCE



Angiogenic switch- tumor exit from dormancy

Imaging the angiogenic switch in ovarian cancer

Transformation

Proliferation

Hypoxia


Dormancy

VEGF

Angiogenesis

Normoxia


Proliferation



Gilead Neoplasia, IJC 2004; Gilad IJC 2005




Imaging the angiogenic switch in ovarian cancer



Gilead Neoplasia, IJC 2004; Gilad IJC 2005




Sprouting Angiogenesis vs Vascular maturation




Sprouting angiogenesis



Michal Weiler-
Sagie



Vascular maturation




Vascular permeability:

biomarker for expression of VEGF



Vascular reactivity:

biomarker for expression of Ang1/Ang2




Angiogenesis and tumor progression


Uncoupling between vascular maturation and permeability:
MLS human epithelial ovarian carcinoma in nude mice



Assaf Gilad et al Int J Cancer 2005



Ang-1
Ang-2



VIENNA
2012

ESMO congress

www.esmo2012.org

מכון ויצמן
FOR SCIENCE




Host-tumor interactions in angiogenesis and vascular maturation

Blue DAPI

Red aSMA

Green biotin-BSA




Gilead et al Int J Cancer 2004

VIENNA
2012 **ESMO** congress


www.esmo2012.org

Fibroblasts recruitment into ovarian carcinoma tumors




Two photon microscopy

Recruitment of fibroblasts into ovarian carcinoma tumors



Subcutaneous skin flap

No tumor



Subcutaneous skin flap

Ovarian carcinoma

Addadi et al intravital microscopy

VIENNA
2012 **ESMO** congress

www.esmo2012.org



Yoseph Addadi

מכון ויצמן למדע
WEIZMANN INSTITUTE OF SCIENCE




Fibroblast trans-differentiation to myofibroblasts

Green MLS EGFP
 ovarian tumor

Blue **alphaSMA-DsRed**
fibroblasts

Red Blood vessels: DiD
iv



Addadi 2012, unpublished



Overcoming antiangiogenic inhibition

Mature extracellular matrix
Anti-angiogenic

MRI of Heparanase expressing tumors

HSPG

heparanase →

Release of bFGF, VEGF

High MW hyaluronan

hyal →

low MW Hyaluronan

NIR imaging of thrombin

fibrinogen

thrombin →

MRI of hyaluronidase

fibrin

NIR & MRI of transglutaminase

tTG →

Fibrin targeted contrast media

Cross-linked fibrin

MRI of angio/endostatin expressing tumors

angiotatin

←

plasminogen

uPA →

plasmin

endostatin

←

collagen

MRI of MMP activity



VIENNA
2012

ESMO

congress

www.esmo2012.org

Neeman et al JMRI 2007


Provisional extracellular matrix
Pro-angiogenic

מכון ויצמן למדע
WEIZMANN INSTITUTE OF SCIENCE




In vitro

Conditioned media from ovarian carcinoma cells




High MW hyaluronan
anti-angiogenic

Low relaxivity




Hyal-2




Low MW hyaluronan
pro-angiogenic

High relaxivity




Hyal-1




Complete degradation
di-tetra saccharides

In vivo

MLS human ovarian carcinoma tumor



Separation of leak and drain: *in vivo* avidin chase




1
Contrast enhancement
(0-3 min postcontrast)

30 Avidin chase
(60-72 postcontrast)


60 Avidin
70 Rate of drain

120 min



Red: signal increase

Green: signal decrease



0.02
-0.02
min -1

VIENNA
2012

ESMO congress

www.esmo2012.org

מכון ויצמן למדע
WEIZMANN INSTITUTE OF SCIENCE



Cancer: An angiogenic disease?

- Angiogenic switch- tumor exit from dormancy
- Angiogenesis and tumor progression
- Angiogenesis and metastasis
- Angiogenesis and response to therapy
- Tumor vascularization, beyond angiogenesis
- Angiogenesis and tumor detection



ENCITE
European Research Council



Acknowledgements

Rinat Abramovitch
Hagit Dafni
Assaf Gilad
Dorit Granot
Liora Shiftan
Yoseph Adaddi
Roni Oren
Michal Weiler-Sagi
Moriel Vandsburger
Gila Meir
Batya Cohen
Ofra Golani

Gera Neufeld, Technion
Eli Keshet, Hebrew University
Laura Benjamin, Harvard
Brian Hemmings, Basel
Leoni Kunz-Schughart, Dresden
Fabian Kiessling, Aachen
Moshe Oren, Weizmann

